Details for Patent: 7,173,038

✉ Email this page to a colleague

Summary for Patent: 7,173,038

Title:	Quinazoline derivatives as VEGF inhibitors
Abstract:	The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R.sup.1 represents halogeno or C.sub.1-3alkyl; X.sup.1 represents --O--; R.sup.2 is selected from one of the following three groups: 1) C.sub.1-5alkylR.sup.3 (wherein R.sup.3 is piperidin-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C.sub.1-4hydroxyalkyl and C.sub.1-4alkoxy; 2) C.sub.2-5alkenylR.sup.3 (wherein R.sup.3 is as defined hereinbefore); 3) C.sub.2-5alkynylR.sup.3 (wherein R.sup.3 is as defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof, processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as a active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of number of disease states including cancer and rheumatoid arthritis.
Inventor(s):	Thomas; Andrew Peter (Macclesfield Cheshire, GB), Stokes; Elaine Sophie Elizabeth (Macclesfield Cheshire, GB), Hennequin; Laurent Francois Andre (Reims Cedex, FR)
Assignee:	AstraZeneca AB (Sodertalje, SE)
Application Number:	10/129,336
Patent Claim Types: see list of patent claims	Compound; Process; Composition;

Drugs Protected by US Patent 7,173,038

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 7,173,038

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	99402759	Nov 05, 1999
	99402877	Nov 19, 1999

PCT Information
PCT Filed	November 01, 2000	PCT Application Number:	PCT/GB00/04181
PCT Publication Date:	May 10, 2001	PCT Publication Number:	WO01/32651

International Family Members for US Patent 7,173,038

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1244647	⤷ Sign Up	C300543	Netherlands	⤷ Sign Up
European Patent Office	1244647	⤷ Sign Up	PA2012015	Lithuania	⤷ Sign Up
European Patent Office	1244647	⤷ Sign Up	CA 2012 00032	Denmark	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.